We envision a better way.


Impel NeuroPharma strives to create life-changing innovative therapies for CNS diseases

Discover More

What We Do

Impel NeuroPharma is focused on developing and providing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. TRUDHESA™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) is now approved for the acute treatment of migraine with or without aura in adults. TRUDHESA was previously known as INP104.

The upper nasal space is surrounded by a rich vasculature that has the potential for injection-like absorption, resulting in more rapid and consistent bioavailability and clinical response. While an ideal target for drug delivery, to date no technology has been able to consistently deliver drugs predictably and consistently to the upper nasal space.

Impel NeuroPharma is investigating utilizing its performance technology to deliver proven treatments for multiple neurological conditions with high unmet need.

Press Releases

Trudhesa ™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s…

Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura…

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for…


1 Data on File